Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Receives FDA Clearance for Whooping Cough Assay

NEW YORK (GenomeWeb) – Luminex said today that it has received clearance from the US Food and Drug Administration for its Aries Bordetella Assay for direct detection and identification of Bordetella pertussis and Bordetella parapertussis.  

The Aries Bordetella Assay identifies bacterial nucleic acids in nasopharyngeal swab specimens obtained from people suspected of having respiratory tract infections attributable to B. pertussis and B. parapertussis, Luminex said. The assay — a real-time PCR-based qualitative in vitro diagnostic test — targets the pertussis toxin promoter and IS1001 repeat sequence in the genomes of the two bacteria. It is indicated for use with Aries Systems that automate testing, from sample preparation through analysis, providing answers in less than 2 hours with minimal hands-on time, the company added.

"The high specificity of our Bordetella Assay combined with the rapid results provided by the Aries platform should lead to more positive patient outcomes," Luminex President and CEO Homi Shamir said in a statement. "The Aries Bordetella Assay is a cost-effective option for lower-volume labs desiring high-performance molecular testing, and is part of a growing menu of tests from Luminex that can be adapted to fit the respiratory testing needs of any clinic."

The company has already achieved CE marking for its Bordetella assay. It is the fourth assay to be cleared by the FDA since October 2015 for use on the Aries system.

The firm said that it is also preparing to submit a Clostridium difficile assay to the FDA later this month, and that it is in the process of completing a Group A Streptococcus clinical trial.

The Aries Bordetella Assay is part of the Luminex respiratory testing menu that also includes Aries Flu A/B & RSV, Verigene RP Flex, and NxTag RPP.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.